855 related articles for article (PubMed ID: 23775962)
1. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.
Hodi FS; Corless CL; Giobbie-Hurder A; Fletcher JA; Zhu M; Marino-Enriquez A; Friedlander P; Gonzalez R; Weber JS; Gajewski TF; O'Day SJ; Kim KB; Lawrence D; Flaherty KT; Luke JJ; Collichio FA; Ernstoff MS; Heinrich MC; Beadling C; Zukotynski KA; Yap JT; Van den Abbeele AD; Demetri GD; Fisher DE
J Clin Oncol; 2013 Sep; 31(26):3182-90. PubMed ID: 23775962
[TBL] [Abstract][Full Text] [Related]
2. Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial.
Larkin J; Marais R; Porta N; Gonzalez de Castro D; Parsons L; Messiou C; Stamp G; Thompson L; Edmonds K; Sarker S; Banerji J; Lorigan P; Evans TRJ; Corrie P; Marshall E; Middleton MR; Nathan P; Nicholson S; Ottensmeier C; Plummer R; Bliss J; Valpione S; Turajlic S
Cell Rep Med; 2024 Mar; 5(3):101435. PubMed ID: 38417447
[TBL] [Abstract][Full Text] [Related]
3. Human tumor genomics and zebrafish modeling identify
Ablain J; Xu M; Rothschild H; Jordan RC; Mito JK; Daniels BH; Bell CF; Joseph NM; Wu H; Bastian BC; Zon LI; Yeh I
Science; 2018 Nov; 362(6418):1055-1060. PubMed ID: 30385465
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of imatinib mesylate in merkel cell carcinoma (neuroendocrine carcinoma of the skin): A Southwest Oncology Group study (S0331).
Samlowski WE; Moon J; Tuthill RJ; Heinrich MC; Balzer-Haas NS; Merl SA; DeConti RC; Thompson JA; Witter MT; Flaherty LE; Sondak VK
Am J Clin Oncol; 2010 Oct; 33(5):495-9. PubMed ID: 20019577
[TBL] [Abstract][Full Text] [Related]
5. Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity.
Newell F; Wilmott JS; Johansson PA; Nones K; Addala V; Mukhopadhyay P; Broit N; Amato CM; Van Gulick R; Kazakoff SH; Patch AM; Koufariotis LT; Lakis V; Leonard C; Wood S; Holmes O; Xu Q; Lewis K; Medina T; Gonzalez R; Saw RPM; Spillane AJ; Stretch JR; Rawson RV; Ferguson PM; Dodds TJ; Thompson JF; Long GV; Levesque MP; Robinson WA; Pearson JV; Mann GJ; Scolyer RA; Waddell N; Hayward NK
Nat Commun; 2020 Oct; 11(1):5259. PubMed ID: 33067454
[TBL] [Abstract][Full Text] [Related]
6. Cross-species genomic landscape comparison of human mucosal melanoma with canine oral and equine melanoma.
Wong K; van der Weyden L; Schott CR; Foote A; Constantino-Casas F; Smith S; Dobson JM; Murchison EP; Wu H; Yeh I; Fullen DR; Joseph N; Bastian BC; Patel RM; Martincorena I; Robles-Espinoza CD; Iyer V; Kuijjer ML; Arends MJ; Brenn T; Harms PW; Wood GA; Adams DJ
Nat Commun; 2019 Jan; 10(1):353. PubMed ID: 30664638
[TBL] [Abstract][Full Text] [Related]
7. MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.
Zhan Y; Guo J; Yang W; Goncalves C; Rzymski T; Dreas A; Żyłkiewicz E; Mikulski M; Brzózka K; Golas A; Kong Y; Ma M; Huang F; Huor B; Guo Q; da Silva SD; Torres J; Cai Y; Topisirovic I; Su J; Bijian K; Alaoui-Jamali MA; Huang S; Journe F; Ghanem GE; Miller WH; Del Rincón SV
J Clin Invest; 2017 Nov; 127(11):4179-4192. PubMed ID: 29035277
[TBL] [Abstract][Full Text] [Related]
8. A Variant in a MicroRNA complementary site in the 3' UTR of the KIT oncogene increases risk of acral melanoma.
Godshalk SE; Paranjape T; Nallur S; Speed W; Chan E; Molinaro AM; Bacchiocchi A; Hoyt K; Tworkoski K; Stern DF; Sznol M; Ariyan S; Lazova R; Halaban R; Kidd KK; Weidhaas JB; Slack FJ
Oncogene; 2011 Mar; 30(13):1542-50. PubMed ID: 21119596
[TBL] [Abstract][Full Text] [Related]
9. The phosphatidyl inositol 3-kinase pathway is central to the pathogenesis of Kit-activated melanoma.
Liang R; Wallace AR; Schadendorf D; Rubin BP
Pigment Cell Melanoma Res; 2011 Aug; 24(4):714-23. PubMed ID: 21595858
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions.
Mao L; Qi Z; Zhang L; Guo J; Si L
Front Immunol; 2021; 12():680407. PubMed ID: 34149718
[TBL] [Abstract][Full Text] [Related]
11. Alternative Treatments For Melanoma: Targeting BCL-2 Family Members to De-Bulk and Kill Cancer Stem Cells.
Mukherjee N; Schwan JV; Fujita M; Norris DA; Shellman YG
J Invest Dermatol; 2015 Sep; 135(9):2155-2161. PubMed ID: 25947358
[TBL] [Abstract][Full Text] [Related]
12. NUAK2: an emerging acral melanoma oncogene.
Namiki T; Coelho SG; Hearing VJ
Oncotarget; 2011 Sep; 2(9):695-704. PubMed ID: 21911917
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive molecular findings in primary malignant melanoma of the esophagus: A multicenter study.
Deng L; Wang HY; Hu CF; Liu XY; Jiang K; Yong JJ; Wu XY; Guo KH; Wang F
Pigment Cell Melanoma Res; 2024 May; 37(3):363-371. PubMed ID: 38158377
[TBL] [Abstract][Full Text] [Related]
14. Molecular profiling of melanoma and the evolution of patient-specific therapy.
Gajewski TF
Semin Oncol; 2011 Apr; 38(2):236-42. PubMed ID: 21421113
[TBL] [Abstract][Full Text] [Related]
15. Multidisciplinary approach and treatment of acral and mucosal melanoma.
Fortuna A; Amaral T
Front Oncol; 2024; 14():1340408. PubMed ID: 38469235
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapy for melanoma: a primer.
Davies MA; Gershenwald JE
Surg Oncol Clin N Am; 2011 Jan; 20(1):165-80. PubMed ID: 21111965
[TBL] [Abstract][Full Text] [Related]
17. The genetic evolution of acral melanoma.
Wang M; Fukushima S; Sheen YS; Ramelyte E; Pacheco NC; Shi C; Liu S; Banik I; Aquino JD; Acosta MS; Levesque M; Dummer R; Liau JY; Chu CY; Shain AH; Yeh I; Bastian BC
bioRxiv; 2023 Oct; ():. PubMed ID: 37904969
[TBL] [Abstract][Full Text] [Related]
18. Molecular Analysis of Murine Kit
Everdell E; Ji Z; Njauw CN; Tsao H
JID Innov; 2024 May; 4(3):100266. PubMed ID: 38585193
[TBL] [Abstract][Full Text] [Related]
19. Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition.
Carvajal RD; Lawrence DP; Weber JS; Gajewski TF; Gonzalez R; Lutzky J; O'Day SJ; Hamid O; Wolchok JD; Chapman PB; Sullivan RJ; Teitcher JB; Ramaiya N; Giobbie-Hurder A; Antonescu CR; Heinrich MC; Bastian BC; Corless CL; Fletcher JA; Hodi FS
Clin Cancer Res; 2015 May; 21(10):2289-96. PubMed ID: 25695690
[TBL] [Abstract][Full Text] [Related]
20. Improved overall survival in melanoma with combined dabrafenib and trametinib.
Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
